BRANDY HUGHES: Open Payments
NPI 1194059162 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,022 in 139 payments from 29 companies in 2025. Trend: 2023 $3,273 · 2024 $3,225 · 2025 $3,022
Food & beverage: $3,022
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 64 | $1,176 |
| Novartis Pharmaceuticals Corporation | 10 | $252 |
| Lundbeck LLC | 8 | $186 |
| UCB, Inc. | 6 | $144 |
| Biogen, Inc. | 6 | $144 |
| Eisai Inc. | 4 | $117 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Axsome Therapeutics, Inc. | 4 | $113 |
| Neurocrine BioSciences, Inc. | 3 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
Products named: QULIPTA, KESIMPTA, VYEPTI, Leqembi, BOTOX, UBRELVY, Symbravo, INGREZZA.
Industry payments across GA — which companies pay providers there.
